menu
    • menu
    [{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"University Hospital, Bordeaux | Hospices Civils de Lyon | INSERM | Universit\u00e9 d'Auvergne","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase IV","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ University Hospital, Bordeaux | Hospices Civils de Lyon | INSERM | Universit\u00e9 d'Auvergne","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Clermont-Ferrand \/ University Hospital, Bordeaux | Hospices Civils de Lyon | INSERM | Universit\u00e9 d'Auvergne"},{"orgOrder":0,"company":"University Hospital, Clermont-Ferrand","sponsor":"INSERM | Universit\u00e9 d'Auvergne","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase IV","graph3":"University Hospital, Clermont-Ferrand","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Clermont-Ferrand \/ INSERM | Universit\u00e9 d'Auvergne","highestDevelopmentStatusID":"11","companyTruncated":"University Hospital, Clermont-Ferrand \/ INSERM | Universit\u00e9 d'Auvergne"},{"orgOrder":0,"company":"Air Liquide Group","sponsor":"ORION Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase I","graph3":"Air Liquide Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Air Liquide Group \/ ORION Clinical Services","highestDevelopmentStatusID":"6","companyTruncated":"Air Liquide Group \/ ORION Clinical Services"},{"orgOrder":0,"company":"Christiana Care Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase IV","graph3":"Christiana Care Health Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Christiana Care Health Services \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Christiana Care Health Services \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Unity Health Toronto \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Boston Children's Hospital","sponsor":"Praxair Distribution","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Boston Children's Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Gas for Inhalation","sponsorNew":"Boston Children's Hospital \/ Praxair Distribution","highestDevelopmentStatusID":"9","companyTruncated":"Boston Children's Hospital \/ Praxair Distribution"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Emergency Medicine Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Emergency Medicine Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Albert Einstein Healthcare Network \/ Emergency Medicine Foundation"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Pharmacology\/Toxicology","graph2":"Undisclosed","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Albert Einstein Healthcare Network \/ Undisclosed"},{"orgOrder":0,"company":"Albert Einstein Healthcare Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Albert Einstein Healthcare Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albert Einstein Healthcare Network \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Albert Einstein Healthcare Network \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Stanley Medical Research Institute | PPD","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Washington University School of Medicine \/ Stanley Medical Research Institute | PPD","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Stanley Medical Research Institute | PPD"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayside Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayside Health \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Nitrous Oxide

    Menu

    Nitrous Oxide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Unity Health Toronto

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Unity Health Toronto

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder, Treatment-Resistant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2021

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Boston Children's Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Boston Children's Hospital

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II/ Phase III

                            Sponsor : Praxair Distribution

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Long-Acting Reversible Contraception.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2019

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Praxair Distribution

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University Hospital, Clermont-Ferrand

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University Hospital, Clermont-Ferrand

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : INSERM | Université d'Auvergne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lumbar Puncture in Emergency Under Nitrous OXide

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 08, 2019

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : INSERM | Université d'Auvergne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Bayside Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bayside Health

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nitrous Oxide for the Treatment of Major Depressive Disorder

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depression.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2019

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            University Hospital, Clermont-Ferrand

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University Hospital, Clermont-Ferrand

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : University Hospital, Bordeaux | Hospices Civils de Lyon | INSERM | Université d'Auvergne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nitrous Oxide for Lumbar Puncture

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 25, 2017

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : University Hospital, Bordeaux | Hospices Civils de Lyon | INSERM | Université d'Auvergne

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Albert Einstein Healthcare Network

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Albert Einstein Healthcare Network

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Emergency Medicine Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adjunctive Nitrous Oxide During ED Incision and Drainage of Abscess

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Abscess.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2017

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Emergency Medicine Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Washington University School of Medicine

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Washington University School of Medicine

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Stanley Medical Research Institute | PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nitrous TRD Bipolar Depression

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 02, 2016

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Stanley Medical Research Institute | PPD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Christiana Care Health Services

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Christiana Care Health Services

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Nitrous Oxide in the ED

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Laceration.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 09, 2016

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Albert Einstein Healthcare Network

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Albert Einstein Healthcare Network

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Joint Dislocation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 08, 2015

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder

                            Details : Nitrous Oxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2015

                            Lead Product(s) : Nitrous Oxide

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth